retatrutide clinical trial dose retatrutide Dosing: Early Insights on How It Might Work ESC 2024: Retatrutide improves lipid

However, oral bioavailability is only about 1%, meaning you need a much higher absolute dose to achieve comparable blood levels to the injectable form

published the results of a phase 3 clinical trial of tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with T2DM, showing significant results in glycemic control and weight loss (Rosenstock et al., 2021)

Potential adverse effects of GLP-1s may include: Delayed gastric emptying: Symptoms of delayed gastric emptying may include nausea, vomiting, abdominal pain, or shortness of breath

The exact mechanism isn't fully understood, but the additional 5-7% weight loss demonstrates GIP's independent contribution beyond GLP-1 alone